Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
ShenzhenPH, Shenzhen, Guangdong, China
Peking University Third Hospital, Beijing, Beijing, China
Beijing Jishuitan Hospital, Beijing, Beijing, China
West China Hospital of Sichuan University, Beijing, Beijing, China
Investigational Site 9903, Tbilisi, Georgia
Investigational Site 9905, Tbilisi, Georgia
Investigational Site 4810, Zamość, Poland
The Second Hospital of Jilin University, Changchun, Jilin, China
Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark
ShenzhenPH, Shenzhen, Guangdong, China
Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
James J. Peters VA Medical Center, Bronx, New York, United States
National Taiwan University Hospital, Yunlin branch, Douliu, Yunlin County, Taiwan
Massachusetts General Hospital, Boston, Massachusetts, United States
Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States
Rocky Mountain Cancer Centers - Swedish, Englewood, Colorado, United States
Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.